Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma CDMO offers integrated end-to-end solutions for development & commercialization of intermediates & APIs for small molecules.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    veranova-m-2025-06-30

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Pegcetacoplan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Apellis, Sobi Report Ph3 Data For EMPAVELI In C3G, IC-MPGN
    Apellis, Sobi Report Ph3 Data For EMPAVELI In C3G, IC-MPGN

    06 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/06/3095128/0/en/Apellis-and-Sobi-Announce-EMPAVELI-pegcetacoplan-Showed-Sustained-Efficacy-at-One-Year-in-Phase-3-Study-for-C3G-and-Primary-IC-MPGN.html

    GLOBENEWSWIRE
    06 Jun 2025
    Share Share
    Sobi's Aspaveli® 52-week Phase 3 Valiant Data in Nephrology
    Sobi's Aspaveli® 52-week Phase 3 Valiant Data in Nephrology

    03 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/invitation-sobis-aspaveli---52-week-phase-3-valiant-data-in-nephrology-302471733.html

    PR NEWSWIRE
    03 Jun 2025
    Share Share
    Apellis' Syfovre faces tough road ahead in GA market
    Apellis' Syfovre faces tough road ahead in GA market

    14 May 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/apellis-weak-syfovre-quarter-signals-uphill-climb-geographic-atrophy-med-mizuho

    FIERCE PHARMA
    14 May 2025
    Share Share
    Apellis' Empaveli for C3G and IC-MPGN Gets FDA Priority Review
    Apellis' Empaveli for C3G and IC-MPGN Gets FDA Priority Review

    01 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/01/3053146/0/en/Apellis-Announces-FDA-Acceptance-and-Priority-Review-of-the-Supplemental-New-Drug-Application-for-EMPAVELI-pegcetacoplan-for-C3G-and-Primary-IC-MPGN.html

    GLOBENEWSWIRE
    01 Apr 2025
    Share Share
    Apellis, Sobi’s Aspaveli Gets EMA Validate For C3G & IC-MPGN Expansion
    Apellis, Sobi’s Aspaveli Gets EMA Validate For C3G & IC-MPGN Expansion

    20 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/02/20/3029307/0/en/Apellis-and-Sobi-Announce-EMA-Validation-of-Indication-Extension-Application-for-Aspaveli-pegcetacoplan-for-C3G-and-Primary-IC-MPGN.html

    GLOBENEWSWIRE
    20 Feb 2025
    Share Share
    EMA Validates Aspaveli Indication Extension For C3G & IC-MPGN
    EMA Validates Aspaveli Indication Extension For C3G & IC-MPGN

    20 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ema-validates-indication-extension-application-for-aspaveli-for-treatment-of-c3g-and-primary-ic-mpgn-302381200.html

    PR NEWSWIRE
    20 Feb 2025
    Share Share